生產、加工、銷售、為一體鈦產品服務商專注 創新 厚德 務實


時間:2022-10-17 來源:本站 點擊:258次



Pumas rally late to clinch Liga MX playoff spot******

MEXICO CITY, Nov. 7 (Xinhua) -- Pumas UNAM recovered from a two-goal deficit to beat defending champions Cruz Azul 4-3 and secure a place in the Liga MX preliminary playoff round on Sunday.。

Arturo Martinez opened the scoring for Pumas at their Olimpico Universitario stadium with a sixth-minute strike before Roberto Alvarado netted three times in 32 minutes to give the visitors a 3-1 lead at halftime.。

Fabio Alvarez pulled a goal back for the hosts just after the restart and Diego Barbosa equalized with a low finish in the 62nd minute following Juan Dinenno's cross.。

Barbosa completed a remarkable comeback when he coolly slotted home from 12 yards after a counterattack.。

The result meant Pumas finished the regular season in 11th place with 21 points from 17 matches.。

In the only other fixture on the last day of the Liga MX regular season, Santos Laguna were held to a goalless home draw by Atletico San Luis.。

Others to qualify for the preliminary playoff round were Toluca, Puebla, Santos Laguna, Cruz Azul, Monterrey, Guadalajara and Atletico San Luis.。

Club America, Atlas, Leon and Tigres UANL advanced directly to the quarterfinals by finishing in the top four. Enditem。

  英国一航班遭遇"炸弹威胁" 战机紧急升空拦截

Pfizer says COVID******

Pfizer said on Friday that a clinical trial of its pill to treat COVID-19 had shown it is highly effective, hailing it as a big step toward ending the pandemic.。

A simple pill to treat the coronavirus at home has been sought since the start of the global health crisis. So far all treatments have been either intravenous or vaccine shots.。

Pfizer's is the second anti-COVID pill after that of Merck, which is actually an influenza medicine rebranded to fight the coronavirus. Pfizer's has been created specifically to fight COVID-19.。

The Pfizer drug called Paxlovid achieved an 89 percent reduction in risk of hospitalization or death among adult patients with COVID-19 who are at high risk of progressing to severe illness, the US company said.。

The results from the middle-to-late stage clinical trial were so strong that Pfizer will stop recruiting new people for the trial, it said.。

Pfizer will submit the data to the Food and Drug Administration as soon as possible as part of its "rolling submission" for Emergency Use Authorization.。

"Today's news is a real game-changer in the global efforts to halt the devastation of this pandemic," said Pfizer CEO Albert Bourla.。

"These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients' lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of 10 hospitalizations," he added.。

Bourla told CNN he hopes the company can submit its authorization request before the Thanksgiving holiday, which this year falls on November 25.。

President Joe Biden said in remarks at the White House that the government has already secured millions of doses of the new medication.。

He said the pill "would be another tool in our toolbox to protect people from the worst outcomes of COVID-19."

The main analysis of the Pfizer pill data looked at numbers from 1,219 adults in North and South America, Europe, Africa and Asia.。

In the days immediately after symptoms appeared, some of them were given the experimental drug and others got a placebo – for five days, every 12 hours.。

Ten people who took the placebo died, while among those who got the Pfizer medication, none did.。

The search for a pill。

Several companies are working on so-called oral antivirals, which would mimic what the drug Tamiflu does for influenza and prevent the disease from progressing to severe.。

Britain on Thursday became the first country to approve an anti-COVID pill, as it greenlit the use of Merck's antiviral drug called molnupiravir to treat patients suffering from mild to moderate coronavirus.。

Pfizer's product is known as a "protease inhibitor" and has been shown in lab testing to jam up the virus' replication machinery.。

If it works in real life, it will likely only be effective at the early stages of infection.。

By the time COVID-19 progresses to severe disease, the virus has largely stopped replicating and patients suffer from an overactive immune response.。

Until now, COVID-19 therapeutics such as monoclonal antibodies and Gilead's remdesivir – authorized for use in the EU under the name Veklury – have been administered intravenously.。

Merck's molnupiravir was initially developed as an inhibitor of influenza and respiratory syncytial virus – two other important acute respiratory infections – by a team at Emory University in Atlanta, Georgia.。

Britain, which has been one of the countries hardest hit by the pandemic, announced on October 20 that it had ordered 480,000 doses of molnupiravir.。

Pfizer is carrying out two other clinical trials with its pill: among people who are not at risk of progressing to severe COVID-19, and among people close to someone with COVID-19 to see if it protects them against the illness.。

Besides Pfizer and Merck, the Swiss pharma giant Roche is also working on a COVID pill.。








黄磊女儿16岁黄多多近照 穿白衬衫文艺清新| 弹道导弹与巡航导弹分类模糊?专家:现代导弹命名需改变| 俄媒:部分动员令后 俄罗斯人争上初级军事训练课| 日本东京7日新增确诊病例555例,政府呼吁民众保持危机感| 83.4米!如何为“中国第一高树”云南黄果冷杉量身高| 连线“香格里拉”这段话,中国防长魏凤和用了两个感叹号| 西装搭配裙子 就是秋冬最IN混搭| 武警福建总队“文艺轻骑队”到定点扶贫村慰问演出记事| 逾50万名香港居民接种首剂新冠肺炎疫苗| “80后”女正厅段颖被查!30岁就已任县长| 首个省级“团购买房”政策来了!贵州发文鼓励商品房团购| 寒露节气吃点啥?中医专家给出这些建议| 多地政府回购商品房,有的计划买近万套新房| 第132届广交会15日线上开幕 参展企业大增| 习近平强调,坚持科技是第一生产力| 身边有人想轻生,我们能做些什么?| 西甲最多进球+最少丢球!国家德比巴萨能进几球&会丢球吗| 信创概念走强,多路资金同时加仓,北上资金“戒酒”,两大白酒股净流出超50亿元|